Cargando…

A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma

BACKGROUND: Our objective was to assess the efficacy and safety of initial hepatic arterial infusion of chemotherapy combined with transarterial chemoembolisation using camrelizumab-eluting Callisphere beads (camrelizumab-DEB-TACE) for treating unresectable hepatocellular carcinoma (HCC). METHODS: E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Xiaonan, Wang, Yang, Ren, Jianzhuang, Han, Xinwei, Bi, Yonghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675937/ https://www.ncbi.nlm.nih.gov/pubmed/38001447 http://dx.doi.org/10.1186/s12885-023-11668-7

Ejemplares similares

Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads
por: Bi, Yonghua, et al.
Publicado: (2022)

Clinical outcomes of doxorubicin-eluting CalliSpheres beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma
por: Bi, Yonghua, et al.
Publicado: (2021)

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
por: Bi, Yonghua, et al.
Publicado: (2022)

Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer
por: Bi, Yonghua, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma
por: Zhou, Tan-Yang, et al.
Publicado: (2020)

Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer: A case series study
por: Bi, Yonghua, et al.
Publicado: (2022)

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients
por: Zhao, Guangsheng, et al.
Publicado: (2021)

Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients
por: Zhou, Guan-Hui, et al.
Publicado: (2018)

Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients
por: Peng, Ning, et al.
Publicado: (2022)

Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases
por: Zhao, Guangsheng, et al.
Publicado: (2021)

Drug‐eluting bead transarterial chemoembolization with medium‐sized versus small‐sized CalliSpheres microspheres in unresectable primary liver cancer
por: Zhang, Jiao, et al.
Publicado: (2021)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres(®) in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres(®) Transarterial Chemoembolization in Liver Cancer (CTILC) Study
por: Sun, Junhui, et al.
Publicado: (2020)

Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study
por: Tong, Huan, et al.
Publicado: (2017)

Clinical management of vascular lake during transarterial chemoembolization with CalliSpheres drug-eluting beads (DEBs) for the treatment of hepatocellular carcinoma
por: Kong, Jian, et al.
Publicado: (2020)

Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
por: Golfieri, R, et al.
Publicado: (2014)

Initial experience of drug-eluting bead transarterial chemoembolization with CalliSpheres(®) microspheres in treating liver metastases patients
por: Zhang, Guangqiang, et al.
Publicado: (2020)

Comparison of CalliSpheres(®) Microspheres Drug-eluting Beads and Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Randomized Controlled Trial
por: Shi, Zhongxing, et al.
Publicado: (2023)

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma
por: Duan, Xuhua, et al.
Publicado: (2022)

Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer
por: Wang, Wenhui, et al.
Publicado: (2022)

CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study
por: Wu, Baolin, et al.
Publicado: (2018)

Occurrence, Related Factors and Prognostic Value of Vascular Lake in Hepatocellular Carcinoma Patients Treated with Drug-Eluting Bead Transarterial Chemoembolization
por: Li, Hao, et al.
Publicado: (2021)

Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma
por: Wang, Cao-ye, et al.
Publicado: (2020)

Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report
por: Martin, Robert CG, et al.
Publicado: (2009)

Hypofractionated Stereotactic Radiotherapy after Transarterial Chemoembolisation Failure in an Unresectable Hepatocellular Carcinoma: A Case Presentation
por: Fiorica, Francesco, et al.
Publicado: (2013)

The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma
por: Li, Hao, et al.
Publicado: (2023)

An investigation of efficacy, safety, and prognostic factors of drug‐eluting beads‐transarterial chemoembolization operation with CalliSpheres(®) Microspheres in treating Chinese hepatocellular carcinoma patients
por: Zhang, Xin, et al.
Publicado: (2019)

Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study
por: Zhou, Tan-Yang, et al.
Publicado: (2021)

Efficacy and Safety of CalliSpheres(®) Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients
por: Liu, Yaohong, et al.
Publicado: (2019)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
por: Nam, Hee Chul, et al.
Publicado: (2016)

CalliSpheres drug-eluting beads transarterial-chemoembolization in the treatment of liver metastases from breast cancer: Initial experience in 14 patients
por: Chang, Xu, et al.
Publicado: (2021)

Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma
por: Razi, Murtuza, et al.
Publicado: (2020)

Drug-eluting beads versus conventional transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis
por: Wang, Zi-Yu, et al.
Publicado: (2023)

Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study
por: Yu, Su Jong, et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g4fd5dg5a1635pbmp5m2bi0lsa